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Background: Low back pain (LBP) is a complex syndrome which includes a nociceptive (NcP) 
component, a neuropathic (NeP) component, or a mixture of components (mixed pain). The NeP 
component (NePC) in LBP is defined as the presence of NeP with or without an NcP. 
Objective: This meta-analysis aimed at assessing the pooled prevalence of NePC in patients with 
LBP and at identifying the factors causing significant heterogeneity in reported prevalence. 
Study Design: Meta-analysis.
Methods: A systematic literature search was carried out, with inclusion of all epidemiological 
studies describing the NeP prevalence levels in LBP patients while using standard diagnostic 
methods. The “pooled prevalence rate (PPR)” of NePC, either on its own or in combination with 
NcP, was calculated. A pre-specified subgroup analysis was carried out, considering LBP duration, 
presence of leg pain, diagnostic method(s), and questionnaire(s) used. 
Results: The meta-analysis included 20 studies relating to a total of 14,269 LBP patients, of 
whom 7,969 patients (55.8%) were identified as presenting with NePC. The pooled PR (95% 
CI) of NePC in patients with LBP was 0.47 (0.40 – 0.54), while the pooled PR of NcP was 0.56 
(0.48 – 0.63). Higher NePC pooled PR values were identified in LBP with leg pain as compared to 
uncomplicated LBP (respectively: 0.60; 0.47 – 0.73 vs 0.27; 0.23 – 0.31; Pinteraction < 0.01). 
Limitations: The quality of the included studies was assessed using ad-hoc criteria. Due to the 
limited number of available studies, one may need to be cautious in reaching conclusions about 
the impact of disease duration on NePC prevalence values. We pooled studies which used a range 
of different diagnostic methods, with putatively different sensitivity/specificity diagnosing levels.
Conclusion: Overall, high NePC prevalence levels were here identified in LBP patients. As the 
pain is a subjective phenomenon and there is no gold standard for the diagnosis of NePC, there is 
the possibility that the pooled effect estimate may alter depending upon the diagnostic method 
used.
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neuropathic (NeP), or mixed pain components (mixed 
pain) (1). The neuropathic pain component (NePC) 
in LBP is defined as the presence of NeP either on its 
own or associated with NcP. Recently, the development 
of multiple measurement scales, such as the 
Low back pain (LBP) is the most frequently observed chronic pain condition (1). It may be associated with leg pain and/or motor/
sensory/reflex deficits in the nerve root distribution 
areas. Thus, LBP can present with nociceptive (NcP), 
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painDETECT questionnaire (PDQ) (2), the neuropathic 
pain questionnaire (NPQ) (3), the Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS) (4), the 
ID-pain (5), the Douleur neuropathique 4 (DN4) (6), 
and the standardized evaluation of pain (StEP) (7) 
have facilitated a better identification of NePC in 
LBP conditions. The extent of involvement of NePC 
in LBP patients is extensively debated, with reported 
prevalence rates being in the range of 28.1% to 71.2% 
(8,9). Recognition of NePC is important, since it may 
significantly affect the patient’s psychological and 
social functioning, while placing considerable financial 
demands on society (10). 
Categorizing LBP as either NcP or NeP is not always 
straightforward (11). A range of different approaches 
have been proposed to facilitate this distinction, includ-
ing physician’s judgement, International Association for 
the Study of Pain (IASP) Treed’s criteria (12), different 
questionnaires (2-7), and finally quantitative sensory 
(QST) and pharmacological testing methods (13). Identi-
fying the presence of NePC in LBP is important, since this 
may present as a challenging treatment/management 
issue (14), typically associated with low rates of treat-
ment success (15). Patients with acute LBP may show 
NeP symptoms similar to those of chronic LBP (CLBP), 
with lack of recognition possibly leading to suboptimal 
drug dosages being administered, with the risk that the 
acute pain condition may persist and become subacute/
chronic (16,17).
The current meta-analysis is aimed at assessing the 
pooled prevalence of NePC in patients with acute, sub-
acute, and chronic LBP and identifying the factors caus-
ing significant heterogeneity in reported prevalence.
Methods
Search Strategy
Two electronic databases (PubMed and EMBASE, 
from their inception until August 2015) were searched 
independently by 2 authors without any language 
restriction. Both full texts and MeSH terms were con-
sidered to identify those epidemiological (e.g., case 
control and cohort) studies focusing on assessing NeP 
prevalence levels in LBP patients. Searches were con-
ducted using synonyms and combinations of the fol-
lowing search terms: “neuropathic pain,” “prevalence,” 
“low back pain,” and “leg pain.” In addition, related 
systematic reviews and selected studies’ reference lists 
were screened for any other relevant study to be in-
cluded in the present analysis. 
Study Selection Criteria
Two authors independently reviewed the titles and 
abstracts of all identified citations as per inclusion and 
exclusion criteria. An abstract was considered to be rel-
evant if it reported original data, originated from epide-
miological studies, and reported the prevalence of NePC 
in patients with LBP. For the present analysis, patients 
were classified in 3 groups: a) patients with exclusive NcP, 
b) patients with exclusive NeP, and c) patients with mixed 
pain (e.g., suffering from both NeP and NcP). NePC was 
here defined as presence of NeP symptoms exclusively 
and/or associated with NcP symptoms.
Studies were excluded if data regarding preva-
lence of NeP in LBP patients were missing/not clearly 
reported, and when diagnostic methods were either 
not standardized or not reported. Single case reports, 
comments, letters, editorials, protocols, guidelines, 
and review papers were excluded. When there were 
multiple publications for the same population, only the 
most detailed report was included. Any discrepancies 
were resolved by a consensus conference. 
Data Extraction and Synthesis
Two authors independently extracted a range of 
relevant information, including first author name, year 
of publication, country of patients’ recruitment, study 
setting, study design, sample size, diagnostic methods 
used to assess NePC, NeP/NePC reported prevalence 
rates (PR) and 95% confidence interval (CI), duration 
of disease, and definitions of NeP, NcP, and NePC. If 
unavailable, both PR and 95% CI of NeP/NePC were 
calculated from the raw data available. If a study re-
ported PRs of NeP and mixed pain separately, they were 
pooled together to get an estimate of NePC.
Quality Assessment
Consistent with the approach of both Hoogen-
doorn et al (18) and De Vet et al (19), all included studies 
were independently assessed for their methodological 
quality by 2 authors. These researchers had developed 
and tested a list of 23 criteria to be used to assess the 
methodological quality of prospective, cohort, and case 
control studies. Out of this list of criteria, Fishbain et al 
(20) selected 10 criteria that were deemed appropriate 
for the assessment of NeP prevalence in LBP. To this list, 
Fishbain et al (20) have added one extra criterion. We 
have excluded 5 questions  and added one (relating to 
the characteristics of recruitment, e.g., consecutive or 
not) question for this study, resulting in a total of 7 cri-
teria , including study design related quality assessment 
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(22). The publication bias was assessed using both the 
funnel plot and the Begg’s test. The Duval and Tweedie 
nonparametric trim-and-fill method was performed to 
further assess the effect of potential publication bias, a 
method which negotiates the lack of studies on a par-
ticular side of the funnel (23). When data were not uni-
formly reported to allow a formal statistical analysis, 
we presented the available data in a narrative format. 
All statistical tests were 2-sided, and a P value < 0.05 
was considered statistically significant, except where 
otherwise specified. Data were analyzed using STATA 
version 11.0 (StataCorp, College Station, TX, USA).
Results 
Search Results
After applying the initial search strategy, a total of 
160 citations were identified (Fig. 1). After reviewing 
the citations, 124 of them were considered ineligible, 
as they were reviews/editorials/case reports, hence not 
meeting the inclusion criteria. In examining the full 
text of the remaining 36 studies and reviewing the re-
lated reference lists, 5 further studies were considered. 
After a detailed evaluation of these 41 manuscripts, 21 
of them were excluded for a range of reasons, which 
are better detailed in Fig. 1. As a result, 20 studies were 
included in the present meta-analysis.
Description of Included Studies 
All the studies had been published between 2004 
and 2015. Most (n = 10; 50%) originated from Europe 
(2,7,9,24-30), followed by Asia (n = 5; 25%) (10,17,31-
33), and Africa (n = 4; 20%) (8,34-36). The study sample 
recruitment site was not reported in one study (37).
Out of these studies, 17 (85%) were cross sec-
tional, 2 were cohort, and one was a case control study. 
Eleven (55%) studies were multi-center (2,10,24-27,29-
31,34,35) whereas the remaining were single-center 
studies (7-9,17,28,32,33,36,37). Twelve (60%) studies 
were carried out primarily to assess the prevalence of 
NeP in patients with LBP, while the remaining focused 
either on the effects of NeP on a range of patient-
reported outcomes or on the validation of a range of 
NeP-related questionnaires. Eighteen (90%) studies 
included patients with LBP as the main clinical concern, 
while 2 studies included patients with multiple pain 
conditions. The LBP etiology was reported in 8 (40%) 
studies (10,17,24,31,32,34-36).
All studies were carried out in hospital settings. 
Most (n = 16) studies had reported a diagnosis of 
measures like clearly defined objective, standard data 
collection procedure, and statistical analysis plan. For 
each of the included studies, each criterion was rated ei-
ther fulfilled (+), unfulfilled (−), or not applicable (NA). 
A quality score for each paper was obtained by counting 
the number of positives obtained; the score was then 
divided by 7 (minus the number of NAs) and multiplied 
by 100, providing the percentage quality score. Studies 
scoring less than 60% were excluded for further review. 
Any discrepancy in quality assessment was discussed and 
internally resolved between 2 authors.
Data Synthesis and Analysis
As the primary outcome measure, we calculated the 
weighed pooled PR of NePC in patients with LBP. The 
weight, Wi, assigned here to each study was the inverse 
of the estimated variance. Where different prevalence 
estimates in the same patient group, using different 
diagnostic methods, were reported those prevalence 
estimates resulting from the most reliable method were 
chosen. For the present meta-analysis, the pooled PR, 
with 95% CI, was reported as a summary measurement, 
with the results being presented as a forest plot. Co-
chran Q and I2 statistics were used to assess heterogene-
ity, with a Q statistic P value of < 0.10, and an I2 value > 
50% having been considered as statistically significant. 
If heterogeneity was identified, the DerSimonian-Laird 
random-effects model was applied; otherwise, the fixed 
effects-model (inverse variance) was considered (21). A 
pre-specified subgroup analysis was carried out to assess 
the source of heterogeneity, according to: i) diagnostic 
method(s) for identification of NeP (e.g., physician- or 
questionnaire-based), ii) duration of LBP (e.g., acute, 
subacute, or chronic), iii) presence of associated leg 
pain, iv) primary objective of the study being/not being 
the assessment of NeP prevalence, v) number of study 
centers involved (e.g., single vs multi-center), and vi) 
questionnaires used for the diagnosis (e.g., LANSS, DN4, 
PDQ, and NPQ). Tests for interaction using summary 
estimates were performed, using the method described 
by Altman and Bland (21).
To evaluate the stability of our results, we also 
performed a one-way sensitivity analysis. The scope of 
this analysis was to evaluate the influence of individual 
studies by estimating the average PR in the absence 
of each study. The present work was performed in ac-
cordance with the guidelines proposed by the Meta-
analysis of Observational Studies in Epidemiology group 
and Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA; supplementary material 1) 
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NePC which relied solely on symptom-based question-
naires, while the sole physician’s criteria were used in 
2 studies (5,27). Only one study (7) reported an NePC 
diagnosis made with the help of both physician’s cri-
teria and symptom-based questionnaires. Most com-
monly used questionnaires included PDQ (n = 7 studies) 
(2,9,17,25,26,28,33), followed by DN4 (6,8,24,36,37), 
and LANSS (6,31,32,34,35) (n = 5 each). Conversely, NPQ 
(n = 2 studies) (10,33) and StEP (n = 1 study) (7) were less 
frequently considered (Table 1).
Quality Assessment
All the studies had a quality score ranging from 
71% to 100%, hence were eligible for inclusion. The av-
erage (SD) score was 92.8% (9.8%) (Table 2). Two stud-
ies presented with a score of 71.4%; in fact, they were 
not characterized by an adequate sample size (e.g., n 
< 50 patients) and had not considered a consecutive 
patient recruitment (10,33). 
Primary Outcome
As a significant heterogeneity was found between 
studies (Cochrane Q ≤ 0.01, I2 = 98), a random effects 
model was chosen (Table 3). The present meta-analysis 
included 14,269 patients with LBP, of whom 7,969 pa-
tients (55.8%) were identified with NePC. The pooled 
PR (95% CI) of NePC in patients with LBP out of all the 
included studies was 0.47 (0.40 – 0.54) (Fig. 2), with 
pooled PR for NePC being in the 0.28 to 0.71 range. 
Sensitivity Analysis
The estimated effect size did not deviate much by 
excluding any study, one at a time, with pooled PR val-
ues ranging between 0.42 and 0.49.
Publication Bias
The visual examination of the funnel plot revealed 
only minimal levels of asymmetry (Fig. 3). This was 
further confirmed by the Begg’s test (P = 0.58) which 
indicated little or no publication bias. The NePC pooled 
Fig. 1. Flow chart showing the number of  citations retrieved by individual searches and the number of  studies included in the 
review.
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PR value (e.g., 0.47; 0.40 – 0.54) obtained using the 
random effects model remained unchanged using the 
Duval and Tweedie’s (23) trim-and-fill analysis.
Sub-group Analysis
With the physician-diagnosis approach, the pooled 
PR of NePC in LBP patients was lower (0.44; 0.32 – 0.55) 
than the pooled PR resulting from the questionnaire-
based diagnosis (0.48; 0.40 – 0.55; Pinteraction = 0.58). Simi-
larly, the pooled PR of NePC was only marginally higher 
(0.49; 0.41 – 0.57) in CLBP patients in comparison with 
patients affected by acute/subacute LBP (0.45; 0.28 – 
Table 1. Characteristics of  20 studies included in the analysis to assess the prevalence rate of  the neuropathic pain component in 
patients with low back pain.
Author, year (Reference 
number of  the study)
Country
Method of  
Diagnosis^
Questionnaire
Sample 
Size
Duration of  
LBP#
Prevalence 
(95% CI)
Study 
Quality$ %
Hassan et al, 2004 (34) SA 1 LANSS 100 Chronic 41 (31.4 – 50.6) 83.3
Kaki et al, 2005 (35) SA 1 LANSS 1,169 Chronic 54.7 (51.8 – 57.5) 100
Freynhagen et al, 2006 (2) Germany 1 PDQ 7,772 Chronic 64.7 (63.6 – 65.8) 100
Freynhagen et al, 2006 (27) Germany 2 - 717 Chronic 33 (29.6 – 36.4) 100
Scholz et al, 2009 (7) UK 1,2* StEP 137 Chronic 54.7 (46.4 – 63) 85.71
Sissi et al, 2010 (31) UAE 1 LANSS 1,134 Chronic 55.4 (52.5 – 58.3) 100
Attal et al, 2011 (24) France 1 DN4 132 Chronic 70.4 (62.6 – 78.2) 100
Beith et al, 2011 (25) England, UK 1 PDQ 343 NR 40.5 (35.3 – 45.7) 85.71
Morsø et al, 2011 (28) Denmark 1 PDQ 145 Chronic 45.5 (37.4 – 53.6) 100
Ouedraogo et al, 2011 (36)
Burkina 
Faso, 
Africa
1 DN4 107 Acute/Subacute, Chronic 49.5 (40 – 59) 100
Smart et al, 2012 (29) Ireland, UK 2 -
464 Acute/Subacute, Chronic 44.8 (40.3 – 49.3)
83.33123 Acute/Subacute 32.5 (24.2 – 40.8)
341 Chronic 49.3 (44 – 54.6)
Walsh et al, 2012 (30) Ireland 1 S-LANSS, DN4* 45 NR 42 (27.6 – 56.4) 85.71
Uher et al, 2012 (9) Czech Republic 1 PDQ
66 Acute/Subacute, Chronic 71.2 (60.3 – 82.1)
10040 Acute/Subacute 70 (55.8 – 84.2)
26 Chronic 73 (56 – 90.1)
Yamashita et al, 2013 (10) Japan 1 NPQ 17 Chronic 29.4 (7.7 – 51) 66.66
Forster et al, 2013 (26) Germany 1 PDQ 1,083 NR 30.7 (28 – 33.4) 83.33
Selimoglu et al, 2013 (37) NR 1 DN4 224 Chronic 55.8 (49.3 – 62.3)
Doualla et al, 2013 (8) Cameroon 1 DN4 167 Chronic 28.1 (21.3 – 35)
Hiyama et al, 2014 (17) Japan 1 PDQ
331 Acute/Subacute, Chronic 42.5 (37.2 – 47.8)
100201 Acute/Subacute 25.3 (19.3 – 31.3)
130 Chronic 31.5 (23.5 – 39.5)
Sakai et al, 2015 (33) Japan 1 NPQ*, PDQ 30 Chronic 43.3 (25.6 – 61) 66.66
Park et al, 2015 (32) Korea 1 LANSS 86 NR 36 (25.8 – 46.1) 100
NR, Not reported; SA, South Africa; UK, United Kingdom; UAE, United Arab Emirates; LANSS, Leeds Assessment of Neuropathic Symptoms and 
Signs; NPQ, Neuropathic Pain Questionnaire; PDQ, PainDETECT Questionnaire; DN4, Douleur Neuropathique 4 questionnaire
^ 1: questionnaire; 2: clinician rated * Standard method considered if more than one method used for the diagnosis of NPC
# Acute: duration of LBP less than 6 weeks; Subacute: duration of LBP 6 to 12 weeks; Chronic: duration of LBP more than 12 weeks.
C.I; Confidence Interval
$ Quality was assessed using scale developed by Fishbain et al (here modified) 
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0.62; Pinteraction = 0.71). Conversely, signifi-
cantly higher pooled PR values of NePC 
were associated with leg pain (0.60; 0.47 
– 0.73) as compared to those conditions 
without an associated leg pain (0.27; 
0.23 – 0.31; Pinteraction < 0.01). When the 
subgroup analysis was performed ac-
cording to the type of screening ques-
tionnaires used, comparable PR were 
obtained with LANSS (0.47; 0.29 – 0.64), 
DN4 (0.49; 0.33 – 0.65), and PDQ (0.48; 
0.34 – 0.63). However, relatively lower 
PR values of NePC were identified when 
the NPQ was used (0.36; 0.90 – 0.64). 
Secondary Outcomes
The pooled PR of mixed pain in pa-
tients with LBP (n = 7 studies) was found 
to be 0.28 (0.23 – 0.34) (Table 4), while 
the pooled PR of sole NeP in patients 
with LBP (n = 7 studies) was found to be 
0.23 (0.11 – 0.34). The pooled PR of NcP 
in patients with LBP in all studies was 
0.56 (0.48 – 0.63).
discussion
The present meta-analysis of 20 
studies, including 14,269 participants, 
found that the PPR of NePC in patients 
with LBP was 47% (40% – 54%), hence 
NePC may need to be considered as 
a significant clinical problem in these 
patients.  One of the major strengths 
of the current study is that we focused 
on both the neuropathic and the noci-
ceptive components, while considering 
not only the chronic, but also the acute/
subacute, LBP conditions. Moreover, 
previous studies considered mathematic 
calculations only to estimate NePC 
pooled PR values, as opposed to the 
formal meta-analysis approach which 
was carried out here. The NePC figure 
(47%) identified is consistent with previ-
ous findings, e.g., Morso et al (45.5) and 
Ouedraogo et al (49.5) (28,36), but it 
is at odds with the figures reported by 
both Fishbain et al (36.6%) and Mehra 
et al (90.4%) (20,38). The studies here 
reported a prevalence of NePC ranging 
from 28.1% to 71.2%, with these levels Ta
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Table 3. Pooled prevalence rates of  NePC in different subgroups of  patients with LBP.
Study Characteristics
Neuropathic pain component Heterogeneity
Studies 
No. of  
Patients
PR 
(95% CI)
P value Cochrane Q I2 P Subgroup#
All studies 14269 20 7969 0.47 (0.40 – 0.54) < 0.01 < 0.01 98.0 NA
Leg pain 
Present 572 5 300 0.60 (0.47 – 0.73) < 0.01 < 0.01 89.9
< 0.01
Absent 479 2 89 0.27 (0.23 – 0.31) < 0.01 < 0.01 97.5
Diagnostic method 
Physician-based 1318 3 520 0.44 (0.32 – 0.55) < 0.01 < 0.01 93.6
0.58
Questionnaire-based 12951 17 4792 0.48 (0.40 – 0.55) < 0.01 < 0.01 97.9
Duration of  pain
Acute/Subacute 364 3 80 0.45 (0.28 – 0.62) < 0.01 < 0.01 90.5
0.71
Chronic 51666 15 40585 0.49 (0.41 – 0.57) < 0.01 < 0.01 97.6
Study Centres
Single center 1293 09 598 0.47 (0.39 – 0.55) < 0.01 < 0.01 87.8
0.53
Multi-center 12976 11 7371 0.46 (0.37 – 0.56) < 0.01 < 0.01 98.8
Primary objective was to assess the prevalence of  NePC in LBP
Yes 5267 12 2373 0.44 (0.36 – 0.52) < 0.01 < 0.01 96.6
0.57
No 9002 08 5596 0.51 (0.41 – 0.60) < 0.01 < 0.01 96.1
Questionnaire used
LANSS 2489 4 1339 0.47 (0.29 – 0.64) < 0.01 < 0.01 85.1
DN4 675 5 337 0.49 (0.33 – 0.65) < 0.01 < 0.01 94.2
PDQ 9740 6 5755 0.48 (0.34 – 0.63) < 0.01 < 0.01 99.1
NPQ 47 2 18 0.36 (0.90 – 0.64) < 0.01 < 0.01 0.00
Comparison between subgroups
NA, Not Available; CI, Confidence Interval; PR, Prevalence Rate; LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; NPQ, Neuro-
pathic Pain Questionnaire; NePC, Neuropathic pain component; PDQ, PainDETECT Questionnaire; DN4, Douleur Neuropathique 4 question-
naire; LBP, low back pain.
of variations possibly being explained by differences 
in inclusion criteria, sample size, study settings, and 
diagnostic methods used (8,9). Furthermore, some di-
agnostic questionnaires fail to identify the mixed pain 
conditions, hence underestimating the presence of NeP 
symptoms (31,35,36). According to the current sensitiv-
ity analysis, excluding any single study did not have 
here any major impact on the combined results, which 
may well suggest that the present meta-analysis results 
are pretty consistent. Furthermore, both a robustness 
of results and lack of publication bias were confirmed.  
Overall, a physician/clinician decision is considered 
to be the gold standard in diagnosing any type of pain, 
with the diagnostic accuracy of screening question-
naires not always being considered satisfactory (39). 
However, similar NePC prevalence levels were identified 
in those studies using questionnaires (0.48; 0.40 – 0.55) 
vs those considering the clinician-based diagnosis (0.44; 
0.32 – 0.55). 
LBP duration was hypothesized to be a possible 
factor associated with different NePC prevalence lev-
els. However, the NePC PPR value was only marginally 
higher in patients with CLBP than in those experienc-
ing acute/subacute LBP (respectively: 0.49; 0.41 – 0.57; 
vs 0.45; 0.28 – 0.62; ns). Indeed, acute and chronic LBP 
cases differ in their etiology and pathophysiology, with 
acute LBP being usually a self-limiting, protective, bio-
logical function of on-going tissue damage. Acute pain 
is mostly nociceptive in origin and occurs secondary to 
stimulation of A-delta and C-polymodal pain receptors 
(16). Conversely, CLBP is in itself a disease process which 
can persist for years after the initial injury and which 
can be refractory to multiple treatment modalities. In-
adequately treated acute pain conditions may be asso-
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Fig. 2. Pooled estimate of  prevalence rate and 95% CIs of  NPC in patients with 
LBP in all the included studies (20 studies) comprising 14,269 patients with 
LBP. The pooled prevalence rate of  NPC in patients with LBP in all the included 
studies (20 studies) was found to be 0.47 (at 95% CI, 0.40 – 0.54).
NPC, neuropathic pain component; LBP, low back pain; CI, confidence interval.
Fig. 3. Funnel plot to assess the publication bias (effect estimates on the horizontal 
scale and study size on the vertical axis).
ciated with NeP symptoms (16) and 
may become chronic. Consistent 
with this, a higher prevalence of 
NePC is typically identified in CLBP 
as opposed to acute/subacute LBP 
(17). 
The presence of leg pain was 
hypothesized as another possible 
factor associated with different 
NePC prevalence levels. As expect-
ed, and consistent with previous 
findings (17), the NePC prevalence 
was significantly higher in patients 
affected by leg pain than in those 
with uncomplicated LBP. Although 
both NeP and NcP mechanisms are 
thought to contribute to leg pain 
in LBP, neuropathic mechanisms 
play a more significant role (1,27) 
Evidence also suggests that patients 
experiencing a radiating leg pain 
may complain of intense pain and 
significant disability (40), delayed 
recovery, and a tendency to chro-
nicity (41). Furthermore, they fre-
quently require surgical interven-
tions for their LBP to be managed 
(42). To better identify the presence 
of NePC in LBP, some questionnaires 
(e.g., PDQ) have been designed 
to specifically include a question 
about the presence of leg pain (12). 
Results of the present meta-analysis 
might not be generalizable to pa-
tients with failed back syndrome 
where the prevalence of NeP is 
more common and the cause for 
NeP is quite different. 
Limitations
The quality of the studies 
selected was assessed using an ad 
hoc, customized scale. Although 
not specifically validated, the scale 
presented has been designed while 
including further assessment cri-
teria to previous instruments. Due 
to the limited number of available 
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studies, one may need to be cautious in concluding 
about the impact of disease duration on NePC preva-
lence values. Furthermore, the quality of data collected 
from those studies whose primary aim was not the 
assessment of NeP prevalence may be questionable. 
Similarly, one could wonder about the appropriateness 
of grouping together studies which used a range of 
different diagnostic methods, with putatively different 
sensitivity/specificity diagnosing levels. To address this 
issue, however, a subgroup analysis based on type of 
questionnaires used was carried out. The limitation of 
current diagnostic methods is that we cannot quantify 
how much neuropathic there is vs. nociceptive to direct 
the clinician to the appropriate therapy. The studies in-
cluded did not present with sufficient data to perform 
a subgroup analysis to estimate NeP prevalence levels 
according to specific clinical conditions/pathologies in-
volved. Finally, only a few studies included patients with 
LBP with an associated leg pain condition (9,28,30), so 
that the results presented may need to be interpreted 
with some caution. There are limited studies from the 
US.
Given the difficulties in treating and managing 
clients affected by low back pain with a neuropathic 
component further research studies with larger sample 
sizes and increased diagnostic accuracy levels should be 
promoted. As pain is subjective phenomenon and as 
there is a lack of a gold standard for the diagnosis of 
NP, there is the possibility that the pooled effect esti-
mate may alter if the diagnostic ability of the available 
and used methods warrant the gold accuracy.
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